Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Laser breakthrough could speed up retinal detachment recovery

NCT ID NCT06468397

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new laser device called iSeelr™ that seals retinal tears during surgery without needing a gas bubble. The goal is to make recovery faster and safer for people with a detached retina. Ten adults aged 50 and older with a specific type of retinal detachment will be enrolled to check if the device works and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 50 years or older. * Willing and able to comply with all study requirements and visits. * Provided written informed consent. Study Eye: * Recent onset as demonstrated by symptoms or diagnosis macular involving rhegmatogenous retinal detachment. * Detachment due to single or multiple retinal tears in the superior region of the retina Fellow eye: • Visual acuity of 6/12 or better. Exclusion Criteria: * History of medical, surgical, or other conditions that, in the opinion of the investigator, would limit study participation e.g. unstable diabetes, poorly controlled hypertension. * Travel limitations that could prevent review at proscribed study intervals or any other time during the study. * Inability to provide informed consent. * Anaesthetic risk factors or inability to lie supine for 1 hour. * Pregnant and/or breast feeding (to be confirmed on treatment day) * Current systemic infection * Current ocular infection * Unable to return for post-treatment visits * Known inability to attend the emergency department in the event of an adverse event. Exclusion criteria in the study eye: * Significant vitreous haemorrhage partially or fully obscuring detailed examination of the retina * Intraoperative identification of tears below the superior region in the area of retinal detachment not identified at the screening visit or during pre-operative examination. Note: Isolated retinal tears in attached retina, identified at any time are NOT an exclusion criterion and may be treated with lase as per standard of care * Clinical signs of PVR (+1 flare, vitreous clumps, pigment clusters on the inferior retina, rolled retinal tear edge, star-fold) * Myopia greater than -4 D spherical equivalent as confirmed by last refraction prior to becoming pseudophakic if cataract surgery has been performed * History of glaucoma or elevated intraocular pressure \>21mmHg * Prior or current intraocular infection Exclusion criteria in the fellow eye: * Visual Acuity worse than 6/12 * Myopia greater than -4D spherical equivalent or axial length greater than 26mm if known * Any potential sight threatening pathology in the fellow eye as determined by the investigator * Extensive lattice degeneration * Unilateral high myopia as determined by the investigator * Family history of retinal detachment * Collagen disorders such as Marfan's or Sticklers syndrome * History of ocular trauma * Evidence of any abnormality of the eye structure as determined by the investigator * Planned surgery during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rhegmatogenous retinal detachment - macula off are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Royal Victorian Eye and Ear Hospital (RVEEH)

    RECRUITING

    East Melbourne, Victoria, 3002, Australia